PROBLEMATIC ISSUES OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS WITH ENDOGENOUS MENTAL DISORDERS
https://doi.org/10.22625/2072-6732-2017-9-1-67-75
Abstract
The aim: to identify changes in mental status due to receive HAART and comprehensive assessment of the biological, behavioral and social factors in adherence to treatment in HIV-infected patients with endogenous mental disorders. Material: The study involved 53 patients with HIV infection and schizophrenia / affective spectrum comorbidity. Results: In the tolerability and adherence to ARV therapy affects not only the neurobiological vulnerability, but also a change in the mental state and condition of the patient social life. After the start of ART mental state of patients with endogenous mental disorders often deteriorates. Depending on their degree of penetration into the central nervous system were observed pronounced effect of ART on the structure of psychopathological symptoms and the course of mental illness in general.
About the Authors
N. G. Neznanov
Saint-Petersburg Science Research Neuropsychiatric Institute named after V.M. Behterev;
First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
N. B. Khalezova
First Saint-Petersburg State Medical University named after academician I.P. Pavlov;
Saint-Petersburg Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
A. A. Khobeish
First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
N. P Petrov
First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
References
1. Mental and behavioral disorders in HIV infection and AIDS: a manual / O.G.Syropyatov, N.A.Dzeruzhinskaya, V.A.Soldatkin, V.I.Krylov, A.Ya.Perehov – K;. Rostov-on-Don; SPb., 2013.- 109 p. (in Russian)
2. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients witih HIV infection. JAMA. 2001 (286) 2857–2864.
3. Benton T, Blume J, Dube B. Treatment Considerations for Psychiatric Syndromes Associated with HIV Infection. HIV Therapy. 2010; 4(2):231-245.
4. Foster R., Olajide D.,Everall I.P.Antiretroviral therapy-induced psychosis: case report and brief review of the literature. 2003 Volume 4, Issue 2 April 2003:139–144.
5. Harris MJ, Jeste DV, Gleghorn A, Sewell DD. Newonset psychosis in HIV-infected patients. J Clin Psychiatry 1991; 52 (9):369–376
6. Bloom FE, Rausch DM. HIV in the brain: pathology and neurobehavioral consequences. J Neurovirol 1997, 3:102–109
7. Rabkin JG, Ferrando S. A ‘second life’ agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psychiatry 1997, 54:1049–1053.
8. Glenn J. Treismana GJ, Kaplina AI. Depression, cognitive impairment, neurologic and psychiatric complications in HIV and antiretroviral drugs. AIDS 2002; 16:1201 -1215.
9. Belyakov N.A. Rasprostranennost psikhitcheskikh rasstroistv u Vitch-inficirovannyh pacientov v Sankt-Peterburge s 2001 po 2013 / N.A.Belyakov, N.G.Neznanov, N.B.Khalezova, A.N.Ivanov // Mejdisciplinarny podkhod k ponimaniu i lecheniu psikhitheskikh rasstroistv: Mif ili Realnost?: Abstracts. scientific. conf. – SPb .: 2014. pp 374-376. (in Russian)
10. Kazakovtsev B.A. Mental health care to the population of the Russian Federation in 2013: Analytical review / B.A.Kazakovtsev, N.K. Demcheva, N.A.Tvorogova – M .: FGBU “FMITSPN” Russian Ministry of Health, 2015. – 223 p.
11. Neznanov N.G. Schizophrenia i Vitch: psychosocialnye i klinitcheskie aspekty / N.G.Neznanov, N.B. Khalezova // Vitch i immunosupressii. – 2014. – T. 6. – number 3. – S. 46-57.(in Russian)
12. Lyketsos G, Treisman GJ. Mood disorders in HIV infection. Psychiatric Annals 2001 (31): 45–49.
13. Mauri MC, Fabiano L, Bravin S, Ricci C, Invernizzi G. Schizophrenic patients before and after HIV infection: a casecontrol study. Encephale 1997, 23:437–441.
14. Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, Brinker-Spence P, Bauer RM, Douglas SD, Evans DL. Depressive and anxiety disorders in women with HIV infection. Am. J. Psychiatry 159, 5789–796 (2002).
15. Thompson A., Silverman B., Dzeng L., Treisman G. Psychotropic Medications and HIV Clinical Infectious Diseases. 2006 (42), Issue 9: 1305-1310
16. Maxwell S, Scheftner WA, Kessler HA, Busch K.Manic syndrome associated with zidovudine. JAMA 1988; 259 (23): 3406.
17. Letendre S., Ellis R., Deutech R. et al. 17th Conference on retroviruses and Opportunistic Infections, San Francisco (Poster №430).
18. Zakharova N.G. Osobennosi naznatchenia vysokoaktivnoy antiretrovirusnoy terapii Vitch-inficirovannym bolnym s narycheniem funkcii centralnoy nervnoy sistemy / N.G.Zaharova, S.E.Toropov, S.I.Parhomenko, V.V.Rassohin, N.A.Belyakov // Victh I immunosuppressii. – 2014 – V.6 – №1. – P.28-29.(in Russian)
Review
For citations:
Neznanov N.G., Khalezova N.B., Khobeish A.A., Petrov N.P. PROBLEMATIC ISSUES OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS WITH ENDOGENOUS MENTAL DISORDERS. Journal Infectology. 2017;9(1):67-75. (In Russ.) https://doi.org/10.22625/2072-6732-2017-9-1-67-75
Views:
4003
.png)
.png)
Email this article 